Icon (ICLR) Scheduled to Post Earnings on Wednesday

Icon (NASDAQ:ICLR) will be posting its quarterly earnings results after the market closes on Wednesday, July 24th. Analysts expect Icon to post earnings of $1.68 per share for the quarter. Icon has set its FY19 guidance at $6.75-6.95 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, May 1st. The medical research company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.03. The firm had revenue of $674.85 million for the quarter, compared to analyst estimates of $668.93 million. Icon had a return on equity of 25.71% and a net margin of 12.56%. Icon’s revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.44 earnings per share. On average, analysts expect Icon to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

NASDAQ:ICLR opened at $153.67 on Tuesday. The business’s 50-day moving average price is $148.90. The firm has a market capitalization of $8.24 billion, a price-to-earnings ratio of 24.43, a P/E/G ratio of 2.10 and a beta of 0.56. Icon has a 52-week low of $118.10 and a 52-week high of $156.34. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.30.

ICLR has been the subject of a number of recent analyst reports. ValuEngine upgraded Yirendai from a “strong sell” rating to a “sell” rating in a research report on Friday, May 3rd. Barclays set a $24.00 price target on Tenet Healthcare and gave the company a “hold” rating in a research report on Wednesday, April 17th. Wolfe Research initiated coverage on Iqvia in a research report on Tuesday, April 2nd. They issued a “market perform” rating for the company. BidaskClub lowered Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th. Finally, Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. Icon presently has an average rating of “Buy” and an average price target of $156.63.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

See Also: What are earnings reports?

Earnings History for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.